Wednesday, July 8, 2026
🇺🇸 FDA

pharma · Advanced Solid Tumor · Hepatocellular Carcinoma

Coherus Oncology

Coherus Oncology patent portfolio — 73 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.

Website Investor relations
333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065, US HQ
2010 Founded
212 Employees
NMPA registrant Type
Company details
Status
Public
HQ
333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065, US
Founded
2010
Employees
212
Programs
25
Drugs
11
Patents
73
Official website ↗ All projects Drug pipeline Patents News & analysis
Intelligence · Patents

Coherus Oncology patents

73 pharmaceutical patents indexed for Coherus Oncology. 0 expire within 24 months.

Coherus Oncology has 73 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.

All patents Expiring ≤12 months Expiring ≤24 months

73 patents

Patent portfolio

Page 1 of 2

  1. US 11667702

    Stable aqueous formulations of aflibercept

    Expires Mon Jun 01 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 11583584

    Stable protein compositions and methods of their use

    Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 11576971

    Method of filling a container with no headspace

    Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 11426446

    Stable aqueous formulations of aflibercept

    Expires Mon Aug 25 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 11400072

    Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy

    Expires Mon Jul 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 11396540

    Methods for making recombinant proteins

    Expires Mon Jul 21 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 11253508

    PPARy agonist for treatment of progressive supranuclear palsy

    Expires Mon Feb 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 11229702

    High concentration formulations of adalimumab

    Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 11135267

    Etanercept formulations stabilized with metal ions

    Expires Mon Sep 30 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 11129876

    Etanercept formulations stabilized with amino acids

    Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 11071782

    Method of filling a container with no headspace

    Expires Mon Jul 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 11001627

    Correctly folded etanercept in high purity and excellent yield

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 11000588

    Etanercept formulations stabilized with sodium chloride

    Expires Mon May 06 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10987405

    Method of reducing formation of etanercept aggregates or fragments

    Expires Mon Apr 22 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10980885

    Method of reducing formation of etanercept aggregates or fragments

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10980884

    Stable aqueous etanercept composition

    Expires Mon Apr 15 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10975138

    Correctly folded etanercept composition

    Expires Mon Apr 08 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10954293

    Correctly folded etanercept in high purity and excellent yield

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10954295

    Correctly folded etanercept in high purity and excellent yield

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10954294

    Correctly folded etanercept in high purity and excellent yield

    Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10947306

    Correctly folded etanercept in high purity and excellent yield

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10888619

    Stable aqueous etanercept composition

    Expires Mon Jan 07 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10822429

    Etanercept formulations exhibiting marked reduction in sub-visible particles

    Expires Mon Oct 29 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10799585

    Stable aqueous formulations of adalimumab

    Expires Mon Oct 08 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10786566

    Stable aqueous formulations of adalimumab

    Expires Mon Sep 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10780163

    Stable aqueous formulations of adalimumab

    Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10772963

    Etanercept formulations stabilized with xylitol

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10772865

    Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10772959

    Stable aqueous formulations of adalimumab

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10772960

    Stable aqueous formulations of adalimumab

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10722579

    Stable aqueous formulations of adalimumab

    Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10716852

    Stable aqueous formulations of adalimumab

    Expires Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 10716854

    Stable aqueous formulations of adalimumab

    Expires Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10716853

    Stable aqueous formulations of adalimumab

    Expires Mon Jul 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10688183

    Stable aqueous formulations of adalimumab

    Expires Mon Jun 18 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10555929

    Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy

    Expires Mon Feb 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10493151

    Etanercept formulations stabilized with sodium chloride

    Expires Mon Nov 28 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10485869

    Etanercept formulations stabilized with meglumine

    Expires Mon Nov 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10376588

    Etanercept formulations stabilized with combinations of sugars and polyols

    Expires Mon Aug 08 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10293049

    Etanercept formulations stabilized with amino acids

    Expires Mon May 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10286072

    Methods of manufacturing stable aqueous formulations of adalimumab

    Expires Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10286071

    Syringe containing stable aqueous formulations of adalimumab

    Expires Mon May 09 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10213508

    Etanercept formulations stabilized with xylitol

    Expires Mon Feb 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10207000

    Stable aqueous formulations of adalimumab

    Expires Mon Feb 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10195275

    Stable aqueous formulations of adalimumab

    Expires Mon Jan 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10159733

    Stable aqueous formulations of adalimumab

    Expires Mon Dec 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10159732

    Stable aqueous formulations of adalimumab

    Expires Mon Dec 20 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10155039

    Stable aqueous formulations of adalimumab

    Expires Mon Dec 13 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Coherus Oncology have?

73 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Coherus Oncology patents expire?

0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.